

and to evaluate each organization's performance. NCA expects to conduct 15 focus groups annually involving a total of 450 hours during the approval period. In addition, NCA expects to conduct mail surveys with a total annual burden of 12,000 hours and will distribute comment cards with a total annual burden of 208 hours. NCA also plans to conduct mail surveys with customers of specific programs (e.g. Headstones and Markers, Presidential Memorial Certificates, State Veterans Cemeteries) to determine levels of service satisfaction. Program specific surveys are estimated at 500 burden hours annually during the approval period. The IG expects to distribute 1,440 surveys to patients with a total annual burden of 240 hours.

Dated: October 8, 2003.

By direction of the Secretary.

Jacqueline Parks,

IT Specialist, Records Management Service.

[FR Doc. 03-26688 Filed 10-22-03; 8:45 am]

BILLING CODE 8320-01-P

**DEPARTMENT OF VETERANS
AFFAIRS**

**Notice of Intent To Grant Exclusive
License**

AGENCY: Department of Veterans Affairs,
Office of Research and Development.

ACTION: Notice of intent.

SUMMARY: Notice is hereby given that the Department of Veterans Affairs, Office of Research and Development, intends to grant to Recovery Pharmaceuticals, Inc., 25 Main Street, Wayland, MA 01778, U.S.A., an exclusive license to practice U.S. Patent Application Serial No.09/070,263, filed April 30, 1998, issuing as U.S. Patent 6,211,194, entitled "Solution Containing Nicotine".

DATES: Comments must be received within fifteen (15) days from the date of this published Notice.

ADDRESSES: Send comments to: Robert W. Potts, Director of Technology Transfer, Department of Veterans Affairs; Attn: 122TT; 810 Vermont Avenue NW; Washington, DC 20420. Telephone: (202) 254-0260; Facsimile: (202) 254-0473; e-mail: bob.potts@hq.mail.va.gov

FOR FURTHER INFORMATION CONTACT:

Copies of the published patent applications may be obtained from the U.S. Patent and Trademark Office at <http://www.uspto.gov>.

SUPPLEMENTARY INFORMATION: It is in the public interest to so license this invention as Recovery Pharmaceuticals, Inc., submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Dated: October 16, 2003.

Anthony J. Principi,

Secretary, Department of Veterans Affairs.

[FR Doc. 03-26689 Filed 10-22-03; 8:45 am]

BILLING CODE 8320-01-P